← Back to Screener
Axsome Therapeutics, Inc (AXSM)
Price$188.69
Favorite Metrics
Price vs S&P 500 (26W)46.53%
Price vs S&P 500 (4W)10.94%
Market Capitalization$9.65B
All Metrics
Book Value / Share (Quarterly)$1.74
P/TBV (Annual)410.04x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)133.68%
Cash Flow / Share (Quarterly)$-1.85
Price vs S&P 500 (YTD)-0.66%
Gross Margin (TTM)92.56%
Net Profit Margin (TTM)-28.69%
EPS (TTM)$-3.69
10-Day Avg Trading Volume0.59M
EPS Excl Extra (TTM)$-3.69
EPS (Annual)$-3.68
ROI (Annual)-118.68%
Gross Margin (Annual)92.56%
Net Profit Margin (5Y Avg)-1038.72%
Cash / Share (Quarterly)$6.35
Revenue Growth QoQ (YoY)65.03%
ROA (Last FY)-50.57%
Revenue Growth TTM (YoY)65.55%
EBITD / Share (TTM)$-3.43
ROE (5Y Avg)-345.24%
Operating Margin (TTM)-27.74%
Cash Flow / Share (Annual)$-2.63
P/B Ratio109.32x
P/B Ratio (Quarterly)104.28x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)14.92x
Net Interest Coverage (TTM)-27.02x
ROA (TTM)-28.23%
EPS Incl Extra (Annual)$-3.68
Current Ratio (Annual)2.11x
Quick Ratio (Quarterly)1.44x
3-Month Avg Trading Volume0.64M
52-Week Price Return80.90%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.94
P/S Ratio (Annual)15.12x
Asset Turnover (Annual)0.68x
52-Week High$191.50
Operating Margin (5Y Avg)-1009.22%
EPS Excl Extra (Annual)$-3.68
CapEx CAGR (5Y)57.20%
Tangible BV CAGR (5Y)18.82%
26-Week Price Return55.28%
Quick Ratio (Annual)1.99x
13-Week Price Return6.77%
Total Debt / Equity (Annual)3.25x
Current Ratio (Quarterly)1.55x
Enterprise Value$9,523.678
Asset Turnover (TTM)0.98x
Book Value / Share Growth (5Y)-24.82%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-28.77%
Cash / Share (Annual)$6.43
3-Month Return Std Dev32.06%
Net Income / Employee (TTM)$-0
ROE (Last FY)-503.89%
Net Interest Coverage (Annual)-27.02x
EPS Basic Excl Extra (Annual)$-3.68
Receivables Turnover (TTM)3.48x
Total Debt / Equity (Quarterly)2.20x
EPS Incl Extra (TTM)$-3.69
ROI (TTM)-69.26%
P/S Ratio (TTM)15.12x
Pretax Margin (5Y Avg)-1038.72%
Revenue / Share (Annual)$12.83
Tangible BV / Share (Annual)$0.20
Price vs S&P 500 (52W)45.81%
Year-to-Date Return3.48%
5-Day Price Return5.98%
EPS Normalized (Annual)$-3.68
ROA (5Y Avg)-70.30%
Net Profit Margin (Annual)-28.69%
Month-to-Date Return11.82%
Cash Flow / Share (TTM)$-4.39
EBITD / Share (Annual)$-3.43
Operating Margin (Annual)-27.74%
LT Debt / Equity (Annual)0.93x
ROI (5Y Avg)-108.06%
LT Debt / Equity (Quarterly)1.33x
EPS Basic Excl Extra (TTM)$-3.69
P/TBV (Quarterly)192.72x
P/B Ratio (Annual)71.94x
Inventory Turnover (TTM)2.16x
Pretax Margin (TTM)-28.77%
Book Value / Share (Annual)$1.16
Price vs S&P 500 (13W)3.90%
Beta0.50x
Revenue / Share (TTM)$12.61
ROE (TTM)-254.14%
52-Week Low$96.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AXSMAxsome Therapeutics, Inc | 15.12x | 65.55% | 92.56% | — | $188.69 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders with limited existing treatment options. The company's pipeline includes four late-stage candidates: AXS-05, AXS-07, AXS-12, and AXS-14, addressing multiple indications in neurology and psychiatry. Axsome targets underserved patient populations where unmet medical needs remain high.